Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Short Interest Update

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) experienced a notable surge in short interest during March. As of March 15th, short interest reached 51,800 shares, representing a remarkable increase of 254.8% from the February 28th figure of 14,600 shares. With an average daily trading volume of 85,100 shares, the current days-to-cover ratio stands at 0.6 days. It is important to note that approximately 0.0% of the company's shares are currently sold short.

Fresenius SE & Co. KGaA Stock Performance

On Thursday, OTCMKTS:FSNUY saw a slight increase of 0.1%, trading up by $0.01 to reach $10.87. A total of 41,135 shares changed hands on that day, compared to the average volume of 54,716 shares. The company’s stock has a fifty-day moving average of $10.10, while the 200-day moving average is $9.43. Fresenius SE & Co. KGaA carries a debt-to-equity ratio of 0.57, a quick ratio of 1.05, and a current ratio of 1.36. Over the past year, the stock has seen a low of $6.57 and a high of $11.23. The company's market capitalization is $24.28 billion, with a price-to-earnings (P/E) ratio of 51.75 and a beta of 1.02.

Fresenius SE & Co. KGaA last announced its quarterly earnings on February 26th. The company reported earnings per share (EPS) of $0.18 for the quarter, along with a revenue of $6.01 billion. Analysts are predicting that Fresenius SE & Co. KGaA will report an EPS of 0.79 for the current fiscal year.

Analysts' Outlook on Growth

In a research note released on February 3rd, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on Fresenius SE & Co. KGaA shares. This rating reflects a positive outlook for the stock.

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA is a healthcare company dedicated to providing products and services for chronic patients. The company's operations are divided into four main segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Notably, the Fresenius Medical Care segment focuses on offering essential products and services for individuals dealing with chronic kidney failure.

Fresenius, Stocks, Short